TY  - JOUR
AU  - Bill, Marius
AU  - Eckardt, Jan-Niklas
AU  - Döhner, Konstanze
AU  - Röhnert, Maximillian-Alexander
AU  - Rausch, Christian
AU  - Metzeler, Klaus H
AU  - Spiekermann, Karsten
AU  - Stasik, Sebastian
AU  - Wurm, Alexander Arthur
AU  - Sauer, Tim
AU  - Scholl, Sebastian
AU  - Schnetzke, Ulf
AU  - Hochhaus, Andreas
AU  - Crysandt, Martina
AU  - Brümmendorf, Tim H
AU  - Krug, Utz
AU  - Wörmann, Bernhard
AU  - Einsele, Hermann
AU  - Hiddemann, Wolfgang
AU  - Görlich, Dennis
AU  - Sauerland, Cristina
AU  - Steffen, Björn
AU  - Neubauer, Andreas
AU  - Burchert, Andreas
AU  - Schäfer-Eckart, Kerstin
AU  - Berdel, Wolfgang E
AU  - Schliemann, Christoph
AU  - Krause, Stefan W
AU  - Hänel, Mathias
AU  - Hanoun, Maher
AU  - Kaufmann, Martin
AU  - Fransecky, Lars
AU  - Braess, Jan
AU  - Schetelig, Johannes
AU  - Middeke, Jan Moritz
AU  - Bullinger, Lars
AU  - Heuser, Michael
AU  - Thol, Felicitas
AU  - Serve, Hubert
AU  - Baldus, Claudia D
AU  - Platzbecker, Uwe
AU  - Müller-Tidow, Carsten
AU  - Válka, Jan
AU  - Šrámek, Jiří
AU  - Weinbergerova, Barbora
AU  - Mayer, Jiri
AU  - Dumas, Pierre-Yves
AU  - Bertoli, Sarah
AU  - Delabesse, Eric
AU  - Récher, Christian
AU  - Pigneux, Arnaud
AU  - Herold, Tobias
AU  - Ganser, Arnold
AU  - Döhner, Hartmut
AU  - Bornhäuser, Martin
AU  - Thiede, Christian
AU  - Röllig, Christoph
TI  - Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.
JO  - Leukemia
VL  - nn
SN  - 0887-6924
CY  - London
PB  - Springer Nature
M1  - DKFZ-2025-02214
SP  - nn
PY  - 2025
N1  - epub
AB  - In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact of individual MR genes within the ELN, clinical, cytogenetic, and molecular data from 4,978 intensively treated AML patients were analyzed. Remission rates and survival outcomes were evaluated. For analyses in context of ELN2022 classification, patients carrying an MR mutation were excluded from the adverse group and analyzed separately; those with co-occurring favorable or intermediate features remained in their respective groups. Overall, 1698 patients (34.1
LB  - PUB:(DE-HGF)16
C6  - pmid:41145671
DO  - DOI:10.1038/s41375-025-02781-6
UR  - https://inrepo02.dkfz.de/record/305540
ER  -